Updates on Chemoradiation for Locally Advanced Esophageal Cancer

Esophageal cancer remains the seventh most common malignancy worldwide and a leading cause of cancer-related mortality, with Australia reporting one of the highest age-standardised incidence rates of esophageal adenocarcinoma globally. Within the southern states of Victoria, South Australia, and Western Australia, the rise of adenocarcinoma linked to chronic reflux and obesity has reshaped the patient profile seen in major oncology centres. Locally advanced disease, encompassing T3 to T4 tumours and node-positive presentations, continues to drive most curative-intent treatment pathways.

Multimodal therapy has become the cornerstone of curative management, with concurrent chemoradiation playing a central role either before surgery or as definitive treatment in those unfit for resection. The 17th World Congress for Diseases of the Esophagus convened global experts to revisit these protocols in light of new immunotherapy evidence, refined radiotherapy techniques, and emerging biomarker science. This summary distils the updates most relevant to clinicians managing patients across the continent.

For Australian multidisciplinary teams, the timing matters. New PBS listings, evolving TGA indications, and an expanding portfolio of cooperative group trials have made 2021 a pivotal year for clinical decision-making. Practice is no longer static but is being rewritten trial by trial, centre by centre.

The CROSS trial legacy and modern reinterpretation

Long-term Dutch CROSS trial follow-up established neoadjuvant chemoradiation with carboplatin and paclitaxel alongside 41.4 Gy of radiotherapy as a global benchmark, demonstrating durable survival benefit for both squamous cell and adenocarcinoma subtypes. Subgroup analyses continue to inform patient selection, with squamous histology showing the most pronounced overall survival gain. Australian centres including Peter MacCallum Cancer Centre in Melbourne have routinely reproduced these outcomes, integrating the regimen into standard preoperative protocols for resectable T2 to T4a disease.

Recent re-examinations have focused on whether the radiation dose is optimal for high-risk features such as bulky nodal disease or R1 margin concerns at thoracoscopic resection. Data presented at the congress suggested that dose-modified schedules may benefit selected patients without prohibitive oesophagitis, although prospective validation is still pending. The CROSS backbone therefore remains intact but is being carefully calibrated.

Integrating immunotherapy with definitive chemoradiation

The CheckMate 648 and KEYNOTE-590 trials have transformed the first-line treatment landscape for unresectable or definitive-intent cases, adding nivolumab or pembrolizumab to platinum-based chemoradiation. Both studies reported meaningful improvements in overall survival, with the greatest absolute benefit observed in tumours expressing elevated PD-L1 combined positive scores. The TGA approval of nivolumab in this setting has begun to flow through Australian prescribing practice, with PBS subsidy anticipated to broaden equitable access.

The practical challenge for treating radiation oncologists is sequencing. Concurrent immunotherapy carries a small but real risk of oesophageal fistula, pneumonitis, and immune-mediated colitis, and Australian multidisciplinary teams in Brisbane and Sydney have begun auditing their early experience carefully. Patient counselling now routinely addresses immune-related adverse events alongside traditional chemotherapy toxicities, reflecting the new complexity of shared decision-making.

Neoadjuvant versus definitive therapy in older and frail patients

Defining optimal therapy for older or comorbid patients remains contentious, particularly relevant to Australia's aging demographic profile and the growing coastal retirement population. The landmark CROSS study and the ESOPEC trial framework both contribute to the conversation, although geriatric-specific data are limited. Decision-making in this group often hinges on functional status, nutritional reserve, and patient values rather than chronological age alone.

Several congress presentations highlighted the role of comprehensive geriatric assessment, frailty indices, and prehabilitation programs in stratifying risk. Australian dietitians and physiotherapists embedded in oesophageal cancer services have played a central role, particularly in regional centres where rural patients face long travel burdens to reach metropolitan surgical hubs. Definitive chemoradiation with close endoscopic surveillance continues to be a reasonable option for those deemed unfit for oesophagectomy.

Refinements in radiation planning and dose

Modern four-dimensional CT planning, respiratory gating, and PET-directed target volume definition have meaningfully reduced cardiac and pulmonary dose. Adaptive radiotherapy, with replanning triggered by interim imaging, is emerging as a way to maintain coverage while sparing organs at risk during the typically protracted treatment course. Proton beam therapy, although not yet widely available within Australia, has shown promise in reducing cardiac exposure in international retrospective series.

Dose escalation above 50 Gy has historically increased toxicity without clear survival benefit, although newer fractionation schedules and simultaneous integrated boost techniques are being revisited. The congress also discussed the role of MRI-guided linear accelerators in identifying residual tumour during treatment, an innovation likely to influence Australian capital city centres over the next decade.

Biomarkers and treatment intensity

Circulating tumour DNA dynamics during chemoradiation are being validated as early indicators of treatment response, with persistent minimal residual disease signalling heightened relapse probability. PD-L1 expression, although imperfect, remains the most clinically actionable biomarker in the immunotherapy era, and ongoing work on HER2, Claudin18.2, and molecular subtypes is reshaping how combination regimens are designed. Recent updates on novel biomarkers for early detection explored how these same tools may eventually identify high-risk Barrett's oesophagus patients before invasive disease develops.

For Australian laboratories, access to comprehensive next-generation panels has historically been uneven, although Medicare rebates for selected molecular tests have improved equity. Pathologists in tertiary centres such as Royal Prince Alfred in Sydney and the Royal Brisbane and Women's Hospital are increasingly integrating multiplex biomarker reporting into routine multidisciplinary discussion.

Australian practice, trials, and multidisciplinary care

Cooperative research through the Trans-Tasman Radiation Oncology Group continues to anchor Australian contributions to international evidence, with active studies in oligometastatic disease and novel radiosensitiser strategies. Telehealth multidisciplinary meetings have bridged gaps between metropolitan tertiary centres and regional hospitals in towns such as Cairns, Launceston, and Wagga Wagga, allowing consistent treatment recommendations across vast geographic distances. Indigenous health outcomes remain a priority, and culturally safe care pathways are being embedded into oesophageal cancer services in the Northern Territory and Western Australia.

Reflecting on these developments, Australian cancer centres should audit their multidisciplinary workflows against the new immunotherapy-supported definitive chemoradiation regimens over the next twelve months, evaluating whether current biomarker testing pathways align with updated international recommendations and whether adaptive radiotherapy techniques can be incorporated into routine planning for suitable candidates.